Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report

详细信息    查看全文

• 作者：Morimasa Kitamura ; Tomomasa Hayashi ; Chiaki Suzuki…
• 关键词：Lenvatinib ; Sorafenib ; Antiangiogenic tyrosine kinase inhibitor ; Thyroid cancer ; Surgery
• 刊名：World Journal of Surgical Oncology
• 出版年：2017
• 出版时间：December 2017
• 年：2017
• 卷：15
• 期：1
• 全文大小：5266KB
• 刊物主题：Surgical Oncology;
• 出版者：BioMed Central
• ISSN：1477-7819
• 卷排序：15

文摘

BackgroundThere are currently no effective therapeutic methods for locally recurrent, metastatic, or progressive radioactive iodine (RAI)-refractory differentiated thyroid cancer. However, multitargeted tyrosine kinase inhibitors (TKIs) such as lenvatinib or sorafenib have been approved for patients with RAI-refractory differentiated thyroid cancer as a second targeted therapy, and these agents can prolong patient survival. However, several cases have been reported that TKIs have caused fatal complications such as fistula formation or bleeding.